Visionary Keynote Interviews + New Poster Award at TIDES

TIDES is coming to San Diego in 6 weeks!  Get a sneak peek of this year's meeting by listening to exclusive interviews with a few of this year's visionary keynote speakers, who provide their perspectives on the current state of the oligonucleotide and peptide industry.

Start planning your team's trip to attend this year's meeting and access 800+ like-minded attendees, 100+ speaker presentations, 70+ exhibitors and 40+ scientific poster presentations.  The $200 registration savings deadline expires on April 10, so secure your seat today: http://bit.ly/1bxzMyX

Plus, all registered attendees gain immediate access to Attendee Connect, the partnering tool that allows you to communicate with fellow attendees before, during and after the meeting.

Stanley T. Crooke, M.D., Ph.D. CEO, Isis Pharmaceuticals, Inc.

The progress of technology has yielded new chemistries like Generation 2.5.  How will that improve the potential of antisense technology?

SC:  Second generation drugs today that we make are significantly better than second generation [drugs] of just a few years ago in that we get about twice as much potency and we have much better tolerated drugs and that's a product of advances in technology.  Generation 2.5, we would expect would give us an increase in potency of about ten-fold...(Listen to the full interview)

You say that you are focused on creating the maximum value for your drugs and technology.  Tactically, how are you going that?

SC:  I think focusing on maximum value is the only hope for the industry in general.  With the technology we have at Isis, we have the benefit of very rapidly being able to take genetic information and convert it to drug.  So step one is to...(Listen to the full interview)

Kunwar Shailubhai, Ph.D., Co-Founder and CSO, Synergy Pharmaceuticals, Inc.

Can you discuss the scientific rationale for developing a uroguanylin peptide analog to treat functional GI disorders?

KS: Two known agonists of GCC that are in clinical development are Linactotide, which is an FDA approved drug and our molecule, plecanatide for functional disorders/chronic constipation and IBS-C. Now, our molecule – plecanatide – is an analogue of uroguanylin whereas Linactotide is an analogue of e-coli enterotoxin. So, I would like to emphasize...(Listen to the full interview)

What challenges do you see the peptide industry facing in the next 5 years?

KS: The biggest challenge when we started working on this compound was to develop large-scale manufacturing.  The next thing that I believe is quite challenging for peptide drugs is formulation. Formulation should be done in a way that.....(Listen to the full interview)

The TIDES 2015 Poster Award

The TIDES 2015 Poster Award, sponsored by AUM LifeTech, Inc. will recognize TIDES 2015 poster presenters whose poster submission and research efforts demonstrate exceptional advances and breakthroughs in the following areas: discovery, pre-clinical and clinical aspects of oligonucleotide based therapeutic research including but not limited to mRNA silencing and manipulation, miRNAs, short and long non coding RNAs, exon skipping, delivery, genome edting, etc.

Three poster award recipients will receive $12,500, $7,500 and $5,000 respectively, in in-kind support/technology/products from AUM LifeTech, Inc. Through this support, awardees will have access to AUM’s next generation oligonucleotide technology that can be used to further awardee’s research. Please refer to www.aumlifetech.com for details on AUM’s RNA silencing and manipulation technology. Submissions from academic and research institutes are especially encouraged, as are submissions from industry. 

To apply for the poster award, you must be a registered TIDES attendee and submit your poster abstract by April 10, 2015 >> Submit your poster abstract today: http://bit.ly/1Iz2PND

Register by Friday, April 10 and receive a $200 Savings. Your $200 Savings Priority Code = 00DCL3R2B. Register here: http://bit.ly/1bxzMyX

Group rates are available for companies registering 4+ attendees.  Call 646-895-7445 to secure your team's seat today.

Sponsorship/Exhibition Opportunities: More than 70 leading and emerging oligonucleotide and peptide companies will be exhibiting or sponsoring this year's TIDES meeting.  Contact Sales Manager Steve Rooney at srooney@ibcusa.com to secure one of our few remaining exhibit spaces and/or spotlight speaking opportunities.

Cheers,

The TIDES Team

Share this article with your social network, just click below to share now!

Share |